Table 6 Comparison of in-hospital and one-year follow-up outcomesin MINOCA, MIOCA and control
Variable | Studies (n) | Pooled Prevalence of each Variable in Study Groups | Â | MIOCA Vs MINOCA (RR (95% CI)) | P-value for RR=1 | Cochrane Q | I2 (%) | P-value for Egger Test | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Sample Size/ Total MIOCA | Pooled Prevalenc in MIOCA (%) | Sample Size/ Total MINOCA | Pooled Prevalenc in MINOCA (%) | Â | Â | Â | Â | Â |
Short-Term Outcomes (In-Hospital Outcomes)a | CV-Death | 5 | 1649/ 64030 | 2.51 (2.39, 2.63) | 37/ 4402 | 0.68 (0.44, 0.97) | 2.7 (1.79, 4.1) | 0.001> | 5.94 | 32.6 | 0.179 |
MACE | 6 | 31912/ 288769 | 10.91 (10.8, 11.03) | 1171/ 20063 | 5.34 (5.03, 5.66) | 3.15 (1.82, 5.47) | 0.001> | 50.90 | 90.2 | 0.134 | |
Cardia Arrest | 1 | 3089/ 160886 | 1.92 (1.85, 1.99) | 55/ 6063 | 0.91 (0.68, 1.18) | 2.12 (1.62, 2.76) | 0.001> | NA | NA | NA | |
MI | 7 | 11119/ 1456110 | 0.72 (0.71, 0.73) | 107/ 245941 | 0 (0, 0) | 7.41 (3.12, 17.57) | 0.001> | 24.81 | 75.8 | 0.073 | |
CVA | 5 | 3906/ 1271503 | 0.25 (0.24, 0.26) | 207/ 238191 | 0 (0, 0) | 1.33 (0.49, 3.59) | 0.576 | 24.15 | 83.4 | 0.07 | |
Stroke | 3 | 8346/ 435056 | 1.38 (1.35, 1.42) | 302/ 23210 | 1 (0.87, 1.14) | 1.26 (0.56, 2.85) | 0.577 | 10.24 | 80.5 | 0.805 | |
HF | 1 | 42/ 4239 | 0.99 (0.71, 1.34) | 2/ 298 | 0.67 (0.08, 2.4) | 1.48 (0.36, 6.07) | 0.589 | NA | NA | NA | |
Cardiogenic Shock | 6 | 8243/ 1431435 | 0.44 (0.43, 45) | 156/ 244166 | 0 (0, 0) | 4.1 (1.61, 10.33) | 0.003 | 72.34 | 93.1 | 0.410 | |
Tamponade | 3 | 3558/ 273043 | 1.25 (1.2, 1.29) | 45/ 17108 | 0.07 (0.02, 0.14) | 4.96 (3.7, 6.66) | 0.001> | 1.57 | 0 | 0.913 | |
Pulmonary Edema | 3 | 1130/ 164059 | 0.59 (0.55, 0.63) | 24/ 6314 | 0.1 (0.02, 0.24) | 1.84 (0.76, 4.47) | 0.179 | 6.99 | 71.4 | 0.785 | |
Pericarditis | 1 | 25/ 2761 | 0.91 (0.59, 1.33) | 0/ 142 | 0 (0, 2.56) | 2.64 (0.16, 43.15) | 0.496 | NA | NA | NA | |
Bleeding | 9 | 27623/ 1562233 | 1.61 (1.59, 1.63) | 1295/ 257081 | 0.34 (0.32, 0.37) | 1.6 (0.82, 3.1) | 0.171 | 170.33 | 95.3 | 0.07 | |
Revascularization | 1 | 44454/ 269931 | 16.47 (16.33, 16.61) | 1872/ 16849 | 11.11 (10.64, 11.59) | 1.48 (1.42, 1.55) | 0.001> | NA | NA | NA | |
-PCI | 6 | 20903/ 38834 | 54.49 (54, 54.99) | 150/ 10189 | 0.94 (0.74, 1.15) | 2.7 (1.54, 5.52) | 0.001> | 139.95 | 96.4 | 0.179 | |
-CABG | 7 | 7899/ 49091 | 14.15 (13.84, 14.46) | 126/ 10601 | 0.23 (0.13, 0.35) | 9.15 (1.31, 63.81) | 0.025 | 585.55 | 99 | 0.212 | |
Long-Term Outcomes (One-Year Follow-up)a | Death | 18 | 27109/ 291233 | 8.97 (8.87, 9.08) | 1221/ 17099 | 6.34 (5.98, 6.72) | 1.48 (1.17, 1.86) | 0.001 | 134.81 | 87.4 | 0.103 |
CV-Death | 10 | 2749/ 66155 | 4.01 (3.86, 4.16) | 92/ 5855 | 1.26 (0.96, 1.59) | 2.23 (1.67, 2.98) | 0.001> | 12.21 | 26.3 | 0.979 | |
MACE | 8 | 3967/ 22160 | 16.49 (16, 16.98) | 185/ 3449 | 4.84 (4.12, 5.61) | 2.13 (1.45, 3.14) | 0.001> | 33.56 | 79.1 | 0.488 | |
MI | 11 | 15363/ 233419 | 6.28 (6.18, 6.38) | 358/ 12856 | 2.24 (1.98, 2.51) | 2.3 (1.79, 5.01) | 0.001> | 102.48 | 90.2 | 0.367 | |
CVA | 4 | 173/ 11849 | 1.04 (0.86, 1.24) | 4/ 836 | 0.08 (0, 0.52) | 2.05 (0.88, 4.77) | 0.098 | 0.7 | 0 | 0.619 | |
Stroke | 8 | 3672/ 33609 | 7.16 (6.88, 7.43) | 195/ 5029 | 186 (1.48, 2.27) | 1.58 (1.25, 1.99) | 0.001> | 9.42 | 25.7 | 0.182 | |
HF | 4 | 547/ 35987 | 1.36 (1.24, 1.48) | 68/ 4372 | 1.36 (1.01, 1.74) | 1.17 (0.91, 1.51) | 0.217 | 0.39 | 0 | 0.927 | |
Re-Bleeding | 3 | 1127/ 9026 | 11.77 (11.11, 12.44) | 27/ 835 | 3.02 (1.92, 4.33) | 1.99 (0.99, 3.99) | 0.051 | 4.19 | 52.3 | 0.056 | |
Revascularization | 2 | 174/ 2492 | 6.77 (5.81, 7.8) | 14/ 240 | 5.02 (2.52, 8.24) | 0.98 (0.05, 19.75) | 0.99 | 13.54 | 92.6 | 0.001> | |
Re-PCI | 4 | 33919/ 15693 | Â | 270/ 2704 | Â | 5.64 (0.25, 127.86) | 0.277 | 833.56 | 99.6 | 0.414 | |
Re-CABG | 5 | 10156/ 177395 | 5.58 (5.47, 5.69) | 199/ 8718 | 1.73 (1.45, 2.04) | 4.05 (1.17, 13.97) | 0.027 | 35.18 | 88.6 | 0.265 | |
Variable | Studies (n) | Pooled Prevalence of each Variable in Study Groups | Â | MINOCAVs Control(RR (95% CI)) | P-value for ROR=1 | Cochrane Q | I2 (%) | P-value for Egger Test | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Sample Size/ Total MINOCA | Pooled Prevalenc in MINOCA | Sample Size/ Total Control | Pooled Prevalenc in Control | Â | Â | Â | Â | Â |
Short-Term Outcomes (In-Hospital Outcomes)a | CV-Death | NA | NA | NA | NA | NA | NA | NA | NA | NA | 0.082 |
MACE | 1 | 1/ 115 | NA | 2/ 266 | 0.75 (0.09, 2.69) | 1.16 (0.11, 12.63) | 0.905 | NA | NA | NA | |
Cardia Arrest | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
MI | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
CVA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
Stroke | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
HF | 1 | 2/ 298 | 0.67 (0.08, 2.4) | 0/ 256 | 0 (0, 1.43) | 4.3 (0.21, 89.11) | 0.346 | NA | NA | NA | |
Cardiogenic Shock | 1 | 2/ 298 | 0.67 (0.08, 2.4) | 1/ 256 | NA | 1.72 (0.16, 18.83) | 0.658 | NA | NA | NA | |
Tamponade | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
Pulmonary Edema | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
Pericarditis | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
Bleeding | 1 | 2/ 298 | 0.67 (0.08, 2.4) | 1/256 | 0.39 (0.01, 2.16) | 1.72 (0.16, 18.83) | 0.658 | NA | NA | NA | |
Revascularization | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
-PCI | 1 | 82/ 8384 | 0.98 (0.78, 1.21) | 15/ 8391 | 0.18 (0.1, 0.29) | 5.47 (3.16, 9.48) | 0.001> | NA | NA | NA | |
-CABG | 1 | 11/ 8384 | 0.13 (0.07, 0.23) | 2/ 8391 | 0.02 (0, 0.09) | 5.51 | 0.026 | NA | NA | NA | |
Long-Term Outcomes (One-Year Follow-up)a | Death | 3 | 82/ 2167 | 3.53 (2.79, 4.36) | 6/ 1525 | 0.33 (0.07, 0.74) | 5.2 (1.27, 20.97) | 0.022 | 3.24 | 38.3 | 0.086 |
CV-Death | 2 | 33/ 1996 | 1.57 (1.05, 2.19) | 2/ 1345 | 0.11 (0, 0.41) | 8.13 (1.37, 48.27) | 0.021 | 1.33 | 25.1 | 0.001> | |
MACE | 1 | 2/ 312 | 0.64 (0.08, 2.3) | 2/ 545 | 0.37 (0.04, 1.32) | 1.75 (0.25, 12.34) | 0.576 | NA | NA | NA | |
MI | 1 | 1/229 | 0.44 (0.01, 2.41) | 2/ 196 | NA | 0.43 (0.04, 4.68) | 0.487 | NA | NA | NA | |
CVA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
Stroke | 2 | 77/ 1996 | 3.69 (2.89, 4.58) | 8/ 1345 | 0.57 (0.21, 1.07) | 4.14 (0.91, 18.72) | 0.065 | 2.24 | 55.4 | 0.001> | |
HF | 1 | 31/ 1774 | 1.75 (1.19, 2.47) | 2/1027 | 0.19 (0.02, 0.7) | 8.97 (2.15, 37.42) | 0.003 | NA | NA | NA | |
Re-Bleeding | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
Revascularization | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
Re-PCI | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
Re-CABG | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |